SCHEMBL10086145

SCHEMBL10086145

COCCn1cc(C(=O)O)c(=O)c2cc(C)ccc21

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
RAB9A P51151 2/20 0.56
HPGD P15428 1/20 0.56
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
MAPT P10636 2/20 0.51
TP53 P04637 1/20 0.49
CNR1 P21554 3/20 0.47
LMNA P02545 2/20 0.47
CNR2 P34972 2/20 0.46
HTT P42858 1/20 0.46
PTGER4 P35408 1/20 0.45
NPC1 O15118 1/20 0.45
CHRM1 P11229 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10084833 0.88 TP53 (0.50) ALDH1A1MAPTTP53CNR1LMNA
SCHEMBL10086154 0.87 LMNA (0.60) ALDH1A1KDM4ERAB9AHPGDTSHR
SCHEMBL4154426 0.86 KDM4E (0.55) ALDH1A1KDM4ERAB9AHPGDTSHR
SCHEMBL9028491 0.83 LMNA (0.63) ALDH1A1TSHRMAPTCNR1LMNA
SCHEMBL7057692 0.83 KDM4E (0.70) ALDH1A1KDM4ERAB9AHPGDTSHR
SCHEMBL13008006 0.82 LMNA (0.52) ALDH1A1KDM4ERAB9AHPGDTSHR
SCHEMBL27794869 0.80 ALDH1A1 (0.72) ALDH1A1KDM4ERAB9AHPGDTSHR
SCHEMBL10086144 0.80 CNR2 (0.49) ALDH1A1KDM4ERAB9AHPGDTSHR
SCHEMBL399326 0.80 LMNA (0.56) ALDH1A1KDM4ERAB9AHPGDTSHR
SCHEMBL3450091 0.79 ALDH1A1 (0.46) ALDH1A1KDM4ERAB9AHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885KDM4E 633/4885RAB9A 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.